title: Translin-associated factor X gene (TSNAX) may be associated with female major depressive disorder in the Japanese population.
abstract: Several investigations have reported that the translin-associated factor X gene (TSNAX)/disrupted-in-schizophrenia-1 gene (DISC1) was associated with major psychiatric disorders including schizophrenia, bipolar disorder (BP), and major depressive disorder (MDD). TSNAX is located immediately upstream of DISC1, and has been shown to undergo intergenic splicing with DISC1. It thus may also be influenced by translocation. To our knowledge, there are no reported gene-based association analyses between TSNAX and mood disorders in the Japanese population. We conducted a case-control study of Japanese samples (158 bipolar patients, 314 major depressive disorder patients, and 811 controls) with three tagging SNPs in TSNAX, selected using HapMap database. In addition, we performed an association analysis between TSNAX and the efficacy of fluvoxamine treatment in 120 Japanese patients with MDD. The MDD patients in this study had scores of 12 or higher on the 17 items of the Structured Interview Guide for Hamilton Rating Scale for Depression (SIGH-D). We defined a clinical response as a decrease of more than 50% in baseline SIGH-D within 8 weeks, and clinical remission as an SIGH-D score of less than 7 at 8 weeks. We found an association between rs766288 in TSNAX and female MDD in the allele/genotype analysis. However, we did not find any association between TSNAX and BP or the fluvoxamine therapeutic response in MDD in the allele/genotype analysis or haplotype analysis. Our results suggest that rs766288 in TSNAX may play a role in the pathophysiology of female MDD in the Japanese population. A replication study using larger samples may be required for conclusive results, since our sample size was small.
authors.affiliation: Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, 470-1192, Japan.
authors.forename: Akiko
authors.initials: A
authors.lastname: Okuda
authors.forename: Taro
authors.initials: T
authors.lastname: Kishi
authors.forename: Tomo
authors.initials: T
authors.lastname: Okochi
authors.forename: Masashi
authors.initials: M
authors.lastname: Ikeda
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Kitajima
authors.forename: Tomoko
authors.initials: T
authors.lastname: Tsunoka
authors.forename: Takenori
authors.initials: T
authors.lastname: Okumukura
authors.forename: Yasuhisa
authors.initials: Y
authors.lastname: Fukuo
authors.forename: Yoko
authors.initials: Y
authors.lastname: Kinoshita
authors.forename: Kunihiro
authors.initials: K
authors.lastname: Kawashima
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Yamanouchi
authors.forename: Toshiya
authors.initials: T
authors.lastname: Inada
authors.forename: Norio
authors.initials: N
authors.lastname: Ozaki
authors.forename: Nakao
authors.initials: N
authors.lastname: Iwata
mesh_terms: D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use; D044466:Asian People / Q000235:genetics*; D016022:Case-Control Studies; D004268:DNA-Binding Proteins / Q000235:genetics*; D003865:Major Depressive Disorder / Q000188:drug therapy / Q000235:genetics*; D005260:Female; D016666:Fluvoxamine / Q000627:therapeutic use; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006239:Haplotypes; D006801:Humans; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D011569:Psychiatric Status Rating Scales; D055815:Young Adult
chemical_list: D018687:Antidepressive Agents, Second-Generation; D004268:DNA-Binding Proteins; C498305:TSNAX protein, human; D016666:Fluvoxamine